-
Under the boom of pharmaceutical companies deploying AI, a number of companies have begun to usher in new breakthroughs
Time of Update: 2023-01-05
【Pharmaceutical Network Market Analysis】In recent years, the layout of AI by pharmaceutical companies has become an industry boom, especially with the help of AI, drug discovery and preclinical stage
-
AstraZeneca China's first rare disease drug Sulirui achieved milestone progress in China, providing new options for rare disease treatment
Time of Update: 2022-09-07
As a prescription drug approved in China for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) in adults and children [1], this change of approval marks Eculizumab.
-
How to treat neuralgia after herpes zoster
Time of Update: 2021-11-03
preventionPrevention, prevention, prevention The earlier treatment of herpes zoster, the better, including adequate antiviral treatment and analgesic treatment, which will help prevent the occurrence of PHN .
The earlier treatment of herpes zoster, the better, including adequate antiviral treatment and analgesic treatment, which will help prevent the occurrence of PHN .
-
Merck and BMS will be under pressure in the future
Time of Update: 2021-09-28
EP Vantage's latest analysis found that compared with 2019, almost all large pharmaceutical companies had improved their sales freshness index last year, with the exception of two companies-Amgen and Bristol-Myers Squibb (BMS) .
-
The National Health Commission released the second batch of catalogs of encouraged generic drugs containing 17 varieties
Time of Update: 2021-04-28
(Insufficient competition) drugs were selected and demonstrated, and the "Second Batch of Encouraged Generic Drugs List" was formulated and released.
It contains 17 varieties:
-
Where is the way home for long back pain
Time of Update: 2021-03-27
Since the back pain of Sister Zhang was mainly caused by the rapid loss of her bones, there was no obvious soft tissue damage, so after receiving the above-mentioned treatment measures, the results had little effect.
-
The application for the listing of IL-6 inhibitors introduced by Baiji Shenzhou was accepted by CDE
Time of Update: 2021-01-25
According to the latest announcement from the Drug Review Center (CDE) of the State Drug Administration of China, EUSA Pharma and Baiji Shenzhou jointly submitted two applications for the listing of siltuximab, an injection of IL-6 inhibitors, which were accepted on January 20.
-
Special dermatitis (AD) new drug! AbbVie oral JAK inhibitor Rinvoq Phase 3 clinical efficacy beat Sanofi/Regenerative Dupixent
Time of Update: 2020-12-27
results showed that in all three clinical studies, Rinvoq treatment significantly improved dermatic removal rates and itching levels in adult and adolescent patients with moderate to severe idiopathic dermatitis compared to placebo.
-
10The new drug breakthrough treatment certification approval fast track can help China's innovation to go global
Time of Update: 2020-12-19
The industry generally believes that the significance of establishing a breakthrough therapeutic drug approval channel is to explore the advantages of products through early clinical data, focus on multi-resource research and development, shorten the development cycle of advantageous products, improve the number of successful approvals, reduce the number of new molecular entities stopping before clinical, so that patients get better treatment at an early stage.
-
Novanme PharmaceuticalCo., Ltd. successfully completes second round of financing
Time of Update: 2020-07-04
, Novanme Pharmaceutical Co., Ltd announced the completion of the second round of financing, successfully obtained $13.8 million in funds In addition to Atlas, an internationally renowned venture
-
The third quarter report performance of vaccine enterprises has blossomed one after another, and the market prospect is promising
Time of Update: 2019-10-28
[pharmaceutical network industry trends] according to data, the global vaccine market in 2017 reached US $27.682 billion, including US $11 billion for adult vaccines and US $16.7 billion for children
-
Hengrui medicine reacquires the fever, and PD-1 monoclonal antibody has obtained two new stage III clinical approvals for indications
Time of Update: 2019-07-17
On July 16, Hengrui pharmaceutical announced that it had recently received the notice of clinical trial of combination therapy of carrizumab for injection (shr-1210) approved and issued by the State D
-
83 drugs, none of which are sold in these hospitals (with a list attached
Time of Update: 2019-02-22
Pharmaceutical Network February 22 - February 20, Heilongjiang Province Medical Security Bureau issued "on the suspension of the quality and efficacy of non-passed generic drugs to evaluate the qualif
-
Consistency assessment, the latest battle, these generic drugs have won again
Time of Update: 2018-06-11
Source: sabilan 2018-06-11 has passed the consistency evaluation and will roll the original research drug in one place? Recently, Guangxi pharmaceutical machinery purchase network released the notice
-
GlaxoSmithKline's achievements in drug research and development
Time of Update: 2014-03-10
Source: Biovalley 2014-3-10 according to statistics, GlaxoSmithKline, a pharmaceutical giant, had 20 drugs or vaccines approved by FDA from 2008 to 2013 This figure also makes GlaxoSmithKline in the b
